- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03798509
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
August 29, 2021 updated by: Hrain Biotechnology Co., Ltd.
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia.
Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Participants with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia can participate if all eligibility criteria are met.
Tests required to determine eligibility include disease assessments, a physical exam, electrocardiograph and blood draws.
Participants receive chemotherapy prior to the infusion of CD19 CAR+ T cells.
After the infusion, participants will be followed for side effects and effect of CD19 CAR+ T cells.
Study procedures may be performed while hospitalized.
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hongliang Fang, doctor
- Phone Number: 021-58552006
- Email: fanghongliang@dashengbio.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Recruiting
- Shanghai General Hospital
-
Contact:
- Xianmin Song, Professor
- Phone Number: 3173 021-63240090
- Email: shongxm@139.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 to 70 Years Old, Male and female;
- Expected survival > 12 weeks;
- ECOG score 0-1;
Bone marrow examination clearly diagnosed as CD19 positive B-cell acute lymphoblastic leukemia and who met one of the following conditions:
- Those who failed to achieve CR after at least 2 courses of standard chemotherapy or had early relapse after complete remission (<12 months) or late relapse after complete remission (≥ 12 months) and failed to achieve CR after 1 course of standard chemotherapy;
- For Ph+ ALL: in addition to receiving at least 2 courses of standard chemotherapy, at least two TKIs should be treated with no complete remission or relapse after complete remission (Patients who cannot tolerate TKI therapy or have TKI treatment contraindications or have T315i mutation are excluded);
- Those who relapse after stem cell transplantation are not affected by previous treatments;
- The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators;
Liver, kidney and cardiopulmonary functions meet the following requirements:
- Creatinine is in the normal range;
- Left ventricular ejection fraction >50%;
- Baseline oxygen saturation>92%;
- Total bilirubin ≤ 2×ULN; ALT and AST ≤2.5 × ULN;
- Able to understand and sign the Informed Consent Document.
Exclusion Criteria:
- Graft-versus-host disease (GVHD), or need to use immunosuppressants;
- Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection;
- Subjects with positive HBsAg or HBcAb and peripheral blood HBV DNA titer detection ≥ 1 × 102 copy number / L; HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; CMV DNA positive; syphilis positive;
- Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
- Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment;
- Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
- Received CAR-T treatment or other gene therapies before enrollment;
- Patients with symptoms of central nervous system;
- Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion;
- The investigators consider other conditions unsuitable for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Human CD19 targeted T Cells Injection
|
Autologous genetically modified anti-CD19 CAR transduced T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DLT
Time Frame: 28 days post infusion
|
28 days post infusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of CAR-positive T cells in circulation
Time Frame: 2 years post infusion
|
2 years post infusion
|
The concentration of CD19-positive B cells in peripheral blood.
Time Frame: 2 years post infusion
|
2 years post infusion
|
Overall response rate (ORR) after administration
Time Frame: 90 days post infusion
|
90 days post infusion
|
Duration of remission (DOR) after administration
Time Frame: 2 years post infusion
|
2 years post infusion
|
Progress Free Survival (PFS) after administration
Time Frame: 2 years post infusion
|
2 years post infusion
|
Overall Survival (OS)after administration
Time Frame: 2 years post infusion
|
2 years post infusion
|
The immunogenicity of Human CD19 targeted T Cells Injection. (the detection of human anti-mouse antibody)
Time Frame: 2 years post infusion
|
2 years post infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 13, 2019
Primary Completion (Anticipated)
January 1, 2022
Study Completion (Anticipated)
January 1, 2024
Study Registration Dates
First Submitted
January 3, 2019
First Submitted That Met QC Criteria
January 8, 2019
First Posted (Actual)
January 10, 2019
Study Record Updates
Last Update Posted (Actual)
August 31, 2021
Last Update Submitted That Met QC Criteria
August 29, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRAIN01-ALL01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumEnzon Pharmaceuticals, Inc.TerminatedLymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T CellUnited States, Australia
Clinical Trials on Human CD19 targeted T Cells Injection
-
Hrain Biotechnology Co., Ltd.Shanghai Zhongshan HospitalRecruitingFollicular Lymphoma | Diffuse Large B-cell Lymphoma | CD19-positiveChina
-
Hrain Biotechnology Co., Ltd.Ruijin HospitalNot yet recruitingAcute Lymphoblastic LeukemiaChina
-
Hrain Biotechnology Co., Ltd.Second Affiliated Hospital of Nanchang UniversityRecruitingCentral Nervous System LymphomaChina
-
Hrain Biotechnology Co., Ltd.Second Affiliated Hospital of Nanchang UniversityRecruitingB-cell Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Recruiting
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Not yet recruitingNon-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-CellChina
-
Hrain Biotechnology Co., Ltd.First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaboratorsRecruiting
-
Hrain Biotechnology Co., Ltd.Shanghai Zhongshan HospitalRecruitingB-cell Non-Hodgkin's LymphomaChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Hrain Biotechnology Co., Ltd.First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...Recruiting